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a  b  s  t  r  a  c  t
Objective:  To compare  signal  intensity  (SI)  correction  using  scale  and  rescale  slopes  with  SI correction
using  SIs  of  spleen  and  muscle  for quantifying  multiphase  hepatic  contrast  enhancement  with  Gd-EOB-
DTPA  by assessing  their  correlation  with  T1 values  generated  from  Look-Locker  turbo-ﬁeld-echo  (LL-TFE)
sequence  data  (ER-T1).
Materials  and methods:  Thirty  patients  underwent  Gd-EOB-DTPA-enhanced  magnetic  resonance  imag-
ing (MRI)  in  this  prospective  clinical  study.  For  each  patient,  breath-hold  T1-weighted  fat-suppressed
three-dimensional  (3D)  gradient  echo  sequences  (e-THRIVE)  were  acquired  before  and  2 (ﬁrst  phase),
10 (second  phase),  and  20 min  (third  phase)  after  intravenous  Gd-EOB-DTPA.  Look-Locker  turbo-ﬁeld-
echo  (LL-TFE)  sequences  were  acquired  before  and  1.5  (ﬁrst  phase),  8 (second  phase),  and  18 min  (third
phase)  postcontrast.  The  liver  parenchyma  enhancement  ratios  (ER)  of  each  phase  were  calculated  using
the SI from  e-THRIVE  sequences  (ER-SI)  and  the T1 values  generated  from  LL-TFE  sequence  data  (ER-T1)
respectively.  ER-SIs  were  calculated  in three  ways:  (1)  comparing  with  splenic  SI  (ER-SI-s),  (2)  comparing
with  muscle  SI  (ER-SI-m),  (3)  using  scale  and  rescale  slopes  obtained  from  DICOM  headers  (ER-SI-c),  to
eliminate  the  effects  of  receiver  gain  and  scaling.  For  each  of  the ﬁrst,  second  and  third  phases,  correlation
and  agreement  were  assessed  between  each  ER-SI  and  ER-T1.
Results:  In the  ﬁrst  phase,  all  ER-SIs  correlated  weakly  with  ER-T1. In  the  second  and  third  phases,  ER-SI-c
showed  a  stronger  linear  correlation  with  ER-T1 (r2 =  0.71–0.72,  p  < 0.01)  than did  ER-SI-s  (r2 =  0.37–0.39,
p  <  0.01)  or  ER-SI-m  (r2 = 0.30–0.41,  p <  0.01).
Conclusion:  SI correction  using  scale  and  rescale  slopes  from  DICOM  data  is  the  most  acceptable  algorithm
for evaluating  delayed-phase  Gd-EOB-DTPA  hepatic  enhancement.
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The assessment of liver function is extremely important for pre-
dicting prognosis in patients with hepatic disease [1]. There are
several methods of staging liver damage. The Child–Pugh clini-
cal classiﬁcation is used to determine the prognosis of chronic
liver disease, mainly cirrhosis [2]. Slow hepatic clearance of indo-
cyanine green (ICG) is associated with increased surgical risk and
poor long-term outcomes [3]. 99mTc-galactosyl human serum albu-
min  is a well-established functional imaging technique for visual
and quantitative analysis of radiopharmaceutical tracer uptake in
the liver [4]. The drawback of the technique is its limited spatial
resolution.





























































Pulse sequence parameters for magnetic resonance imaging.
Parameter LL-TFE e-THRIVE
TR (ms) 12.0 3.5
TE (ms) 1.7 1.7
Flip angle (◦) 7 10
Acquisition 2D 3D
Slice thickness (mm)  10.0 1.5
Acquisition matrix 112/66 320/250
RFOV (%) 68 80
SENSE factor (direction) 2.0 (AP) 1.9 (AP)
Fat-saturation No Yes
Acquisition phases Unenhanced and 1.5, 8,
and 18 min  after
administration
Unenhanced and 2, 10,
and 20 min  after
administration
Acquisition time (s) 15.0 18.5
LL-TFE, Look-Locker turbo ﬁeld echo; e-THRIVE, enhanced three-dimensional T140 M. Onoda et al. / European Jour
Gadoxetate disodium-gadolinium ethoxybenzyl diethylenetri-
mine pentaacetic acid (Gd-EOB-DTPA) has recently come into
idespread use in clinical practice. It is a magnetic resonance
maging (MRI) contrast agent that has both extracellular and
epatocyte-speciﬁc capabilities. The former characteristic enables
ynamic imaging, which reveals the vascularity of the hepatic
arenchyma and hepatic lesions, although the dynamic early arte-
ial phase may  be hampered due to a low volume compared
ith other gadolinium agents. The latter characteristic offers hep-
tocyte/hepatobiliary images – generally acquired 20 min  after
dministration – that can visualize focal hepatic lesions as areas
f hypointensity in the surrounding enhancing parenchyma [5,6].
Studies have investigated the relationship between liver
arenchymal enhancement during the hepatobiliary phase of Gd-
OB-DTPA-enhanced MRI  and liver function [7–9]. They have found
hat the signal intensity (SI) of enhanced liver parenchyma is sig-
iﬁcantly lower in patients with severe liver dysfunction, because
f impaired Gd-EOB-DTPA uptake. SI evaluations also have limita-
ions. One is that the SI is deﬁned on an arbitrary scale that can
ary considerably according to prescan calibration. An MR  pres-
an process includes setting the radiofrequency (RF) ampliﬁer and
xing the scale of the SI to acquire optimal images for each scan.
n Gd-EOB-DTPA-enhanced examinations, because T2-weighted
mages (T2WI)  and diffusion-weighted images (DWI) are usually
cquired between the equilibrium and hepatobiliary phases, a sec-
nd calibration process is required for hepatobiliary phase image
cquisition. For that reason, the SIs in the hepatobiliary phase can-
ot be directly compared with those of the precontrast images.
nother limitation of SI evaluations is that SI can be inﬂuenced
y system performance and imaging parameters (e.g., magnetic
trength, B1-ﬁeld heterogeneity, repetition time, echo time, lon-
itudinal relaxation time [T1], and transverse relaxation time [T2
r T2*]) [10,11]. In comparison, the T1 value is essentially an abso-
ute value at the same static magnetic ﬁeld strength, and there is a
inear relationship between the relaxation rate (R1, deﬁned as the
eciprocal of the T1 value) and the concentration of contrast agent
12,13]. This applies to Gd-EOB-DTPA. There are a few studies show-
ng that the T1 value can be used with high accuracy to determine
he Child–Pugh classiﬁcation by evaluating enhancement with Gd-
OB-DTPA [14]. However, it is difﬁcult to measure T1 values in the
bdomen directly because of patient motion (e.g., breathing and
eartbeat). Therefore, the SI of liver parenchyma is still widely used
or assessing hepatic contrast enhancement. In previous studies,
he SI was adjusted for pre- and post-contrast images using the SIs
f various reference organs (e.g., spleen [15,16], erector spinae mus-
le [16,17]) or a phantom [18] in the same plane. Another method
s to use scaling and rescaling factors obtained from the MR  con-
ole. The SI displayed on the MR  console is affected by scaling of the
ixel value. The SI calculated using the scale and rescale slopes is
egarded as the “real” SI value (i.e., ﬂoating point value), as it is no
onger affected by receiver gain or scaling of the displayed image
ixel values [19,20]. The technique is considered relatively reliable,
ut it has not been applied to Gd-EOB-DTPA-enhanced MRI.
We sought to compare SIs corrected using scale and rescale
lopes with SIs adjusted using the reference SIs of muscle and
pleen on multiple phases by quantifying their correlation with T1
alues.
. Materials and methods
.1. SubjectsThis prospective clinical study followed the principles of the
eclaration of Helsinki. The ethics committee of our institution
pproved the study, and informed consent was obtained in written
orm from all patients who participated.high-resolution isotropic volume excitation; TR, repetition time; TE, echo time;
RFOV, rectangular ﬁeld of view; SENSE, sensitivity encoding.
LL-TFE uses a non-slice-selective inversion pulse as a pre-pulse.
From January 2011 to April 2011, a total of 157 consecutive
patients underwent Gd-EOB-DTPA-enhanced MRI  for a known or
suspected liver tumour. Three patients with Child–Pugh C status
were excluded because of insufﬁcient enhancement on MRI  during
the Gd-EOB-DTPA hepatobiliary phase. Ninety-two patients were
excluded for the following reasons: motion artefact due to inade-
quate breath holding (n = 29), and misregistration of slice location
between phases (n = 63). The remaining 30 patients were evalu-
ated. This group included 15 patients with normal liver function
tests, eight with chronic hepatitis, and seven with liver cirrhosis.
2.2. Data acquisition
Gd-EOB-DTPA (EOB-Primovist®; Bayer Pharma AG, Berlin,
Germany) was used as the hepatocyte-speciﬁc contrast agent. All
patients received Gd-EOB-DTPA at a dose of 0.025 mmol/kg body
weight. It was administered at 2 mL/s through an intravenous line
placed in an antecubital or cephalic vein. It was ﬂushed with 35 mL
of 0.9% saline at the same rate.
MRI  was  performed using a 32-channel phased-array surface
coil on a 3.0 T system (Achieva X-series®; Philips Medical Systems,
Eindhoven, The Netherlands).
In all patients, both breath-hold T1-weighted fat-suppressed
three-dimensional (3D) gradient echo sequences (enhanced 3D
T1-high resolution isotropic volume excitation [e-THRIVE]) and
breath-hold Look-Locker turbo ﬁeld echo (LL-TFE) sequences were
acquired during a single examination. The e-THRIVE sequences
were acquired before and at 2 (ﬁrst phase), 10 (second phase), and
20 min  (third phase) after Gd-EOB-DTPA administration. The LL-TFE
sequences were acquired before and at 1.5 (ﬁrst phase), 8 (second
phase), and 18 min  (third phase) after Gd-EOB-DTPA administra-
tion. An LL-TFE sequence was acquired as a single axial slice at the
level of the porta hepatis. Details of each pulse sequence are in
Table 1.
2.3. Image analysis
The SI displayed on the MR  console is affected by scaling of the
pixel value. It is calculated during two scaling processes using the
scale and rescale slopes. The ﬁrst scaling process is performed to
store data in a limited number of bits. The second is used to dis-
play the stored data properly on the MR  console. We decoded the
displayed SI by referring to scale and rescale slopes on the digital
imaging and communication in medicine (DICOM) headers using
the Extended MR  WorkSpace 2.6 (Philips Medical Systems, Eind-
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cquired from the DICOM tags (0028, 1053) and (2005, 100E). The
orrected SI was calculated as follows:
orrected SI = Displayed SI
scale slope ∗ rescale slope (1)
The SIs of the liver parenchyma, erector spinae muscle, and
pleen were measured on the e-THRIVE precontrast, ﬁrst-, second-,
nd third-phase images. The SI for liver parenchyma was  obtained
y positioning a circular region of interest (ROI) with an area
f 50–60 pixels on e-THRIVE images from four imaging series.
wo abdominal radiologists with 7 and 12 years of experience,
espectively, placed three ROIs on areas of liver parenchyma free
f focal hepatic lesions, major branches of the portal or hepatic
ein, or imaging artefacts, making sure to place the ROIs at the
ame positions on the liver for each patient. On visual assessment,
o examination displayed a difference in degree of enhancement
etween left and right lobes in any phase, including the precontrast
hase. The mean of the three ROI measurements was recorded as
he SI of the liver in each phase. For each of the 2, 10, and 20 min
hases, the enhancement ratio based on the SI (ER-SI) for each
atient was calculated by each of the following three algorithms:
he SI of the liver parenchyma was adjusted by the SI of the spleen
ER-SI-s), the erector spinae muscle (ER-SI-m), and by the scale and






R-SI-m = (SIliver/SImuscle)post − (SIliver/SImuscle)pre
(SIliver/SImuscle)pre
(3)
R-SI-c = (SIliver/[SS · RSS])post − (SIliver/[SS · RSS])pre
(SIliver/[SS · RSS])pre
(4)
here SIliver, SIspleen, and SImuscle are the signal intensities of the
iver parenchyma, spleen parenchyma, and erector spinae muscle;
S is the scale slope; and RSS is the rescale slope. In each equa-
ion, (SI ratio)pre is the SI ratio before Gd-EOB-DTPA administration,
nd (SI ratio)post is the ratio after Gd-EOB-DTPA administration. To
valuate interobserver variability, measurements were performed
ndependently twice by different observers. The mean of the values
f the two observers was used as the measurement for each area.
The Philips Research Integrated Development Environment
PRIDE) T1 ﬁtting tool written in Interactive Data Language 6.3 (IDL,
isual Information Solutions, Boulder CO, USA) was employed to
easure the T1 values using data from the LL-TFE sequence. Mul-
iple images acquired during signal recovery after a preparation
ulse were regarded as parametric images and the T1 relaxation
ime was calculated from every pixel of these images. PRIDE depicts
he T1 value on a pixel-by-pixel basis on a colour distribution map.
he same ROI method was applied to the T1 map  of the liver
arenchyma on the same slice that was used for the e-THRIVE
mage. The enhancement ratio based on the T1 value (ER-T1) for
able 2
ummary of the T1 value of liver and signal intensity of liver, spleen, and muscle acquired
Parameter Precontrast First phas
T1 value of liver (ms)a 851 ± 77 (702–1058) 484 ± 76 
SI  of livera 723 ± 206 (464–1167) 856 ± 169
SI  of spleenb 715 ± 159 (376–1045) 918 ± 205
SI  of muscleb 621 ± 211 (297–1273) 721 ± 177
ata are means ± standard deviations. Numbers in parentheses are ranges.
he ﬁrst-, second-, and third-phase data were acquired 1.5, 8, and 18 min  after contrast
dministration for determining signal intensity.
a Two observers individually measured three ROIs.
b Two observers individually measured an ROI. Radiology 84 (2015) 339–345 341
each of the 1.5, 8, and 18 min  phases was  calculated using the
following equation:
ER-T1 =
(1/T1post ) − (1/T1pre )
1/T1pre
(5)
where T1pre is the T1 precontrast value, and T1post is the T1 postcon-
trast value
2.4. Statistical analysis
Interobserver agreement was  assessed using Cohen 
coefﬁcients for binary measures and the intraclass correlation
coefﬁcient (ICC) for continuous measures. Continuous variables
are reported as means with standard deviations (SD) and range.
The single regression analyses and the Bland–Altman technique
were used to evaluate for correlation between ER-T1 and ER-SI-m,
ER-SI-s, or ER-SI-c for the ﬁrst, second, and third phases. A p value
of <0.01 was  considered statistically signiﬁcant. The upper and
lower limits of agreement were deﬁned as the mean difference
±1.96 (SD). In the single regression analyses, the coefﬁcient of
determination (r2) was  used to examine the strength of the associ-
ation between ER-T1 and ER-SI-s, ER-SI-m, and ER-SI-c. Statistical
analyses were performed with a commercial software package
(SPSS version 11.0; SPSS, Chicago IL, USA).
3. Results
The T1 values (mean ± SD) for liver parenchyma on the pre-
contrast and at 1.5, 8, and 18 min  after administration (ﬁrst,
second, and third phases, respectively) in the 30 patients
were 851 ± 77 ms  (702–1058 ms), 484 ± 76 ms  (357–640 ms),
427 ± 105 ms  (270–769 ms), and 385 ± 117 ms (229–807 ms),
respectively (Table 2). The T1 value for liver parenchyma decreased
with increasing study phase in 29 of the 30 patients. T1 maps made
it possible to show the differences between precontrast and post-
contrast T1 values as differences in colour (Fig. 1a). Thus, in 29
patients, liver parenchyma on e-THRIVE was  visually the brightest
at 20 min after administration (Fig. 1b). The SI of liver parenchyma
was the highest during the second phase. The SIs showed higher
SD than T1 values for liver parenchyma in all phases (Table 2). ER-
T1 and ER-SI-c increased steeply between contrast injection and
the acquisition of Phase 1, followed by gradual increases. ER-SI-m
increased continuously at the same rate until the end of the exam-
ination period. ER-SI-s increased very little during the ﬁrst phase
and then gradually increased. Fig. 2 illustrates a plot of one patient.
On imaging analysis, the interobserver variability measure showed
good agreement, with ICCs of 0.77–0.99 for continuous measures
(Table 3).Fig. 3 and Table 4 display the relation and agreement between
ER-T1 and ER-SI-m, ER-SI-s, and ER-SI-c by phase. In the ﬁrst phase,
each of these parameters had a weak (ER-SI-c, r2 = 0.15, p < 0.05)
or a nonsigniﬁcant (ER-SI-s, r2 = 0.04, p = 0.13; ER-SI-m, r2 = 0.04,
 at each time point.
e Second phase Third phase
(357–640) 427 ± 105 (270–769) 385 ± 117 (229–807)
 (516–1133) 951 ± 201 (529–1275) 726 ± 157 (443–1054)
 (472–1384) 680 ± 210 (216–1092) 452 ± 180 (146–946)
 (291–1005) 502 ± 193 (188–977) 300 ± 132 (134–780)
 administration for determining the T1 value and 2, 10, and 20 min after contrast
342 M. Onoda et al. / European Journal of Radiology 84 (2015) 339–345
Fig. 1. Sixty-seven-year-old man  with Child–Pugh A cirrhosis suspected of having hepatocellular carcinoma. (a) T1 map images generated from Look-Locker turbo ﬁeld echo
(LL-TFE) sequences acquired before and 1.5, 8, and 18 min  after administration of contrast. The T1 map  image shows the differences in T1 values as colour distributions. (b)
T1-weighted images using enhanced three-dimensional T1 high-resolution isotropic volume excitation (e-THRIVE) sequences before and 2, 10, and 20 min after contrast
administration.
Table 3
Interobserver agreement for the T1 value of liver and signal intensity of liver, spleen, and muscle.
Parameter Precontrast First phase Second phase Third phase
T1 value of liver 0.98 (0.96, 0.99) 0.99 (0.98, 1.00) 0.99 (0.98, 1.00) 0.99 (0.98, 0.99)
SI  of liver 0.94 (0.88, 0.97) 0.85 (0.70, 0.93) 0.92 (0.84, 0.96) 0.95 (0.68, 0.98)
SI  of spleen 0.83 (0.67, 0.91) 0.84 (0.70, 0.92) 0.92 (0.83, 0.96) 0.94 (0.87, 0.97)
SI  of muscle 0.98 (0.95, 0.99) 0.85 (0.70, 0.92) 0.84 (0.70, 0.92) 0.77 (0.55, 0.89)
SI, signal intensity.










(he ﬁrst-, second-, and third-phase data were acquired 1.5, 8, and 18 min  after contr
or  determining signal intensity. = 0.13) correlation with ER-T1. During the second and third
hases ER-SI-c showed a stronger linear relationship with ER-T1
r2 = 0.71–0.72, p < 0.01) than did ER-SI-s (r2 = 0.37–0.39, p < 0.01) or
R-SI-m (r2 = 0.30–0.41, p < 0.01). Although both ER-T1 and ER-SI-c
ig. 2. Sixty-seven-year-old man  with Child–Pugh A cirrhosis suspected of hav-
ng  hepatocellular carcinoma. Time-intensity curves for the enhancement ratio (ER)
ased on the T1 value (ER-T1) and signal intensity. The latter is adjusted with spleen
ER-SI-s) or muscle (ER-SI-m) intensity or the scaling and rescaling factor (ER-SI-c).ministration for determining the T1 value and 2, 10, and 20 min  after administration
during the second and third phases showed similar trends in mea-
surements (Table 4), there was a bias between ER-T1 and ER-SI-c;
the variability in disagreement increased as the average increases
with fun shape on the Bland–Altman plots (not shown). During the
third phase, ER-SI-s, ER-SI-m, and ER-SI-c showed stronger positive
linear correlations with ER-T1 than during any other phase.
Table 4
Bland–Altman analysis comparing ER-T1 and either ER-SI-m, ER-SI-s, or ER-SI-c at
each phase.
Parameter Mean difference SD Limit of agreement
Lower Upper
ER-T1 vs. ER-SI-s
1st phase −0.83 0.15 −1.14 −0.52
2nd  phase −0.59 0.22 −1.03 −0.16
3rd  phase −0.59 0.29 −1.17 −0.01
ER-T1 vs. ER-SI-m
1st phase −0.72 0.23 −1.18 −0.26
2nd  phase −0.35 0.22 −0.79 0.09
3rd  phase −0.14 0.32 −0.79 0.50
ER-T1 vs. ER-SI-c
1st phase −0.34 0.16 −0.66 −0.01
2nd  phase −0.19 0.13 −0.45 0.08
3rd  phase −0.26 0.17 −0.61 0.09
M. Onoda et al. / European Journal of Radiology 84 (2015) 339–345 343












Bomparison of ER-T1 at 1.5 min  and ER based on signal intensity (SI) 2 min after G
0  min  after administration. (c, f, i) Comparison of ER-T1 at 18 min  and ER based on
. Discussion
Of the three methods for correcting SI, ER-SI-c showed the
trongest positive correlation with ER-T1. The unique features of
ur study were that the hepatic enhancement SI values were
ompared with those of the T1 value at three time points after Gd-
OB-DTPA administration, and SIs were corrected using scale and
escale slopes from the DICOM data. Several studies have shown
he relationship between liver function and T1 relaxation time.
amimura et al. showed that the reduction rate of the T1 relax-
tion time of liver parenchyma could distinguish Child–Pugh A and
 from normal liver better than the relative enhancement of the-DTPA administration. (b, e, h) Comparison of ER-T1 at 8 min and ER based on SI
l intensity 20 min  after administration. Dotted lines are the regression lines.
liver using SI [23]. In their study, the SI of paravertebral muscle
and the spleen were used as the SI reference for liver parenchyma,
but the scale and rescale slopes were not used. Also, they calcu-
lated the reduction rate of the T1 relaxation time at only one time
point (20 min  after Gd-EOB-DTPA administration). Because liver
enhancement with this method depends on the time needed for
uptake and excretion of Gd-EOB-DTPA, we  compared the relation-
ship between the SI and T1 value indices for hepatic enhancement
at three time points after Gd-EOB-DTPA administration.
Whereas almost all of the liver parenchymal enhancement on
20 min  e-THRIVE images was the brightest of all phases, the SIs









































































[44 M. Onoda et al. / European Jour
he reason appears to be that the biliary duct shows very high SI
n e-THRIVE images at 20 min  due to excretion of Gd-EOB-DTPA,
o the liver parenchyma SI is adjusted lower. The adjustment of
I is mainly attributed to the scale and rescale slopes. The same
xplanation applies to the ﬁnding that the SIs of spleen and muscle
t 20 min  were low, thus verifying the signiﬁcance of SI adjustment
or evaluating hepatic enhancement with Gd-EOB-DTPA.
ER-SI-c was signiﬁcantly correlated with ER-T1 during the hepa-
obiliary phases (10 and 20 min  postcontrast), suggesting that
I can be used to assess hepatic enhancement with Gd-EOB-
TPA in the hepatobiliary phase by making adjustments using
he scale and rescale slopes to reduce the inherent problem of
Is varying considerably because of the prescan. Generally, SI of
iver on T1WI  increases when Gd-EOB-DTPA is taken up by liver
arenchyma [14]. The linear correlation is most valid for SI with
 low contrast agent concentration because T1 effects, and not
2* effects, predominantly affect SI [24]. During the hepatobi-
iary phase, the relationship between SI and the Gd-EOB-DTPA
oncentration in liver parenchyma may  be linear. However, the
land–Altman plots indicated a bias between ER-SI-c and ER-T1
uring the hepatobiliary phase. ER-SI-c tended to be lower than ER-
1. In this study, SI reduction was observed in some T1WIs  because
f other inﬂuences (e.g., B1 ﬁeld heterogeneity). This ﬁnding indi-
ates that the adjustments in this study could not completely
liminate the factors potentially inﬂuencing SI [25]. Such small dif-
erences can lead to large errors during rigorous assessment of the
ime course of hepatic enhancement (e.g., pharmacokinetic analy-
is).
Neither ER-SI-s nor ER-SI-m showed a good linear correla-
ion with ER-T1 at any of the time points. It was  because, aside
rom the disadvantage of using SI (i.e., an arbitrary scale), the SIs
f spleen and muscle are themselves variable before and after
nhancement. Fatty inﬁltration or mild enhancement of the erec-
or spinae muscle may  cause measurement errors [18]. Portal
enous pressure, especially in patients with chronic liver dis-
ase, can inﬂuence splenic arterial blood ﬂow [26]. The ﬂuctuating
I of spleen or muscle might directly inﬂuence the ER of liver
arenchyma.
At 2 min  after administration, each ER based on SI (ER-SI-s, ER-
I-m, ER-SI-c) showed a weak or nonsigniﬁcant correlation with
R-T1. A possible reason for this is the difference in the sequences
etween LL-TFE and e-THRIVE: e-THRIVE is a three-dimensional
1-weighted gradient echo technique that requires a longer time
or data acquisition than LL-TFE. As a result, arterial enhancement
urves and peak values differ on a local level, as contrast agent
excited blood protons) may  ﬂow off the tissue during acquisition
f 3D data in the early phase. Thus, the e-THRIVE sequence may not
e applicable to pharmacokinetic analysis, which requires accurate
uantitative data concerning hepatic enhancement throughout the
xamination.
Our study has some limitations. First, correlation between ER-
1 and ER-SI might have been hampered because the LL-TFE and
-THRIVE sequences were performed at time points differing by
0–120 s. During this time, Gd-EOB-DTPA uptake by hepatocytes
ould increase to some degree. We  believe, however, that the
hanges in the enhancement pattern can be evaluated and factored
n. Second, we attempted to eliminate any inﬂuence of calibra-
ion by using SI ratios between liver and spleen or muscle or with
cale and rescale slopes. However, we used single-source paral-
el RF transmission technology, which is split between two ports
hat are located 90◦ apart with horizontal symmetry. The technol-
gy tends to cause B1 inhomogeneity in the abdominal region at
igh magnetic ﬁeld strength [27]. The consistency of the SI may  be
mproved even more by correcting other factors, including B1-ﬁeld
eterogeneity and fat suppression. Further study is needed in these
reas.
[
[ Radiology 84 (2015) 339–345
5. Conclusions
SI correction using scale and rescale slopes from DICOM data is
an acceptable algorithm for assessing hepatic enhancement with
Gd-EOB-DTPA during the hepatobiliary phase.
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